Cutaneous T Cell Lymphoma
Conditions
Brief summary
This is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous T-cell lymphoma (CTCL).
Interventions
DRUGDurvalumab
Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
RADIATIONRadiation Therapy
Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntarily provide written IRB-approved consent * Age ≥ 18 years * Histologically proven CTCL * Stage IIB-IV CTCL with ≥2 cutaneous tumors assessable for response * At least one cutaneous tumor amenable to radiation therapy. Must have at least 1 tumor assessable for response that will not undergo radiation. * Adequate organ function * Prior treatment is allowed if at least 4 weeks have elapsed since last chemotherapy and/or radiation and the subject has recovered from all treatment related toxicity
Exclusion criteria
* Prior allogeneic stem cell transplant. * Prior treatment with a PD-1/PD-L1 inhibitor * Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment. * Current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab. * Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection. * History of hypersensitivity to durvalumab or any excipient * Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab. * Female subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control * Male subjects who are not employing an effective method of birth control * Uncontrolled current medical illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris,unstable cardiac arrhythmia and/or psychiatric illness or other condition that in the opinion of the investigator would limit compliance with study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients that respond to treatment | 1 year post treatment | Overall Response Rate (ORR) is defined as the percentage of patients that obtain a Complete Response (CR) or Partial Response (PR) to treatment. A global composite scoring system will be used to determine response. Skin, nodes, viscera and blood will be assessed. |
| The percentage of patients that completely respond to treatment | 1 year post treatment | Complete Response Rate (CRR) is defined as the percentage of patients that obtain Complete Response (CR) to treatment. A global composite scoring system will be used to determine response. Skin, nodes, viscera and blood will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to response | 1 year post treatment | The time to response is measured from the start of the treatment until criteria are met for CR or PR. A global composite scoring system will be used to determine response. Skin, nodes, viscera and blood will be assessed. |
| Duration of overall response | 1 year post treatment | The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrence or PD (Progressive disease) is objectively documented. A global composite scoring system will be used to determine response and progression. Skin, nodes, viscera and blood will be assessed. |
| Progression free survival time | 1 year post treatment | Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death. A global composite scoring system will be used to determine progression. Skin, nodes, viscera and blood will be assessed. |
| Time to next treatment | 1 year post treatment | Time to next treatment is defined as the duration of time from start of study treatment to next treatment or death of any cause, whichever comes first. |
Countries
United States
Outcome results
None listed